796738-71-1

Basic information

• Product Name: N-(2-Methyl-4-nitrophenyl)-4-(3-pyridinyl)-2-pyrimidinamine
• Synonyms: N-(2-Methyl-4-nitrophenyl)-4-(3-pyridinyl)-2-pyrimidinamine;N-(2-Methyl-4-nitrophenyl)-4-(3-pyridyl)-2-pyriMidineaMine;2-PyriMidinaMine, N-(2-Methyl-4-nitrophenyl)-4-(3-pyridinyl)-;N-(2-methyl-4-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine
• CAS NO: 796738-71-1
• Molecular Formula: C₁₆H₁₃N₅O₂
• Molecular Weight: 307.30672
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 796738-71-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 560.7±60.0 °C(Predicted)
• Appearance: /
• Density: 1.344±0.06 g/cm3(Predicted)
• PKA: 2.66±0.12(Predicted)
• CAS DataBase Reference: N-(2-Methyl-4-nitrophenyl)-4-(3-pyridinyl)-2-pyrimidinamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-Methyl-4-nitrophenyl)-4-(3-pyridinyl)-2-pyrimidinamine(796738-71-1)
• EPA Substance Registry System: N-(2-Methyl-4-nitrophenyl)-4-(3-pyridinyl)-2-pyrimidinamine(796738-71-1)

Safety Data

• Hazardous Substances Data: 796738-71-1(Hazardous Substances Data)

Usage

Description

N-(2-Methyl-4-nitrophenyl)-4-(3-pyridinyl)-2-pyrimidinamine is a chemical compound that serves as a valuable intermediate in the synthesis of various pharmaceutical agents, particularly those related to imatinib mesylate, which is an antitumor drug.

Uses

Used in Pharmaceutical Industry:
N-(2-Methyl-4-nitrophenyl)-4-(3-pyridinyl)-2-pyrimidinamine is used as a key intermediate in the preparation of imatinib impurities and phenylpyrimidinamine derivatives. These derivatives are related to imatinib mesylate, which is a potent antitumor agent used in the treatment of various types of cancer.
N-(2-Methyl-4-nitrophenyl)-4-(3-pyridinyl)-2-pyrimidinamine plays a crucial role in the development and synthesis of new and improved cancer therapeutics, contributing to advancements in oncology and the fight against cancer.

Upstream product

• 55314-16-4 3-(N,N-dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one 
• 7149-70-4 2-bromo-5-nitrotoluene 
• 66521-66-2 4-pyridin-3-ylpyrimidin-2-ylamine 
• 99-52-5 2-methyl-4-nitro-benzenamine 
• 483324-01-2 2-chloro-4-(pyridin-3-yl)pyrimidine 

Downstream Products

• 112696-91-0 2-methyl-N₁-[4-(pyridine-3-yl)-pyrimidin-2-yl]benzene-1,4-diamine 
• 1352242-48-8 2-methyl-N₁-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine 

Relevant articles and documents

Live-cell imaging and profiling of c-Jun N-terminal kinases using covalent inhibitor-derived probes

c-Jun N-terminal kinases (JNKs) are involved in critical cellular functions. Herein, small-molecule JNK-targeting probes are reported based on a covalent inhibitor. Together with newly developed two-photon fluorescence Turn-ON reporters and chemoproteomic studies, we showed that some probes may be suitable for live-cell imaging and profiling of JNKs.

Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors

Imatinib is a clinically important ATP analogue inhibitor that targets the tyrosine kinase domain of the intracellular Abl kinase and the PDGF receptor family. Imatinib has revolutionised the treatment of chronic myeloid leukaemia, which is caused by the oncogene Bcr-Abl and certain solid tumours that harbor oncogenic mutations of the PDGF receptor family. As a leading kinase inhibitor, imatinib also provides an excellent model system to investigate how changes in drug design impact biological activity, which is an important consideration for rational drug design. Herein we report a new series of imatinib derivatives that in general have greater activity against the family of PDGF receptors and poorer activity against Abl, as a result of modifications of the phenyl and N-methylpiperazine rings. These new compounds provide a platform for further drug development against the therapeutically important PDGF receptor family and they also provide insight into the engineering of drugs with altered biological activity.

N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to an N-phenyl-2-pyrimidine-amine derivative showing a superior effect on tumor, lung cancer, gastric cancer, etc. of warm-blooded animals and its salt. The present invention also relates to a process for preparing the compound and a pharmaceutical composition for the prevention and treatment of such diseases as tumor, lung cancer, gastric cancer, etc., which comprises the compound as an active ingredient.